相关实验视频

Updated: Jun 30, 2025

Operational and Intervention Effects of Targeted Tuina in Lumbar Intervertebral Disc Degeneration Model Rabbits

Operational and Intervention Effects of Targeted Tuina in Lumbar Intervertebral Disc Degeneration Model Rabbits

Published on: July 21, 2023

埃沃迪胺通过Nrf2和MAPK通路改善椎间盘退化

Tian Xie¹, Xi Gu¹, Ruijie Pan²

¹Department of Orthopedics, Wuhan Hospital of Traditional Chinese Medicine, No. 49 Lihuangpi Road, Jiang'an District, Wuhan, 430014 China.

|March 18, 2024

概括

埃沃迪胺通过保护线粒体功能障碍,细胞外基质降解和炎症来缓解椎间盘退化 (IDD). 这种天然化合物激活Nrf2通路并抑制MAPK通路,为IDD提供了潜在的治疗策略.

科学领域:

生物化学生物化学
细胞生物学细胞生物学
病理学病理学病理学

背景情况:

椎间盘退化 (IDD) 涉及细胞外基质 (ECM) 降解,反应性氧物种 (ROS) 生产和炎症.
埃沃胺因其抗炎作用和维护线粒体抗氧化功能而闻名,但其在IDD中的作用尚不清楚.

研究的目的:

研究埃沃迪胺对椎间盘退化 (IDD) 的治疗作用和潜在机制.

主要方法:

通过针刺建立了IDD的体内大鼠模型.
初级核脉细胞 (NPC) 用三甲过氧化物 (TBHP) 进行治疗,以诱导氧化应激和衰老.
评估了细胞活力,线粒体ROS,线粒体膜潜力,ECM降解和炎症反应.
关键通路 (Nrf2,MAPK,HO-1) 的基因和蛋白质表达被使用RT-qPCR,西式斑点和免疫组织化学分析.

主要成果:

埃沃迪胺治疗缓解了NPCs中TBHP诱导的线粒体功能障碍和氧化应激.
埃沃迪胺逆转了TBHP诱导的ECM降解,并抑制了NPCs的炎症反应.
在体内大鼠模型中,埃沃迪胺治疗改善了IDD进展.
埃沃胺促进了Nrf2通路的激活,并抑制了NPC中MAPK通路的信号传递.

结论:

埃沃迪胺有效地改善了IDD的进展.
埃沃胺的保护作用通过抑制线粒体功能障碍,ECM降解和炎症来介导.
埃沃迪胺通过Nrf2/HO-1和MAPK信号通路发挥其治疗作用.

关键词:

埃沃迪胺是什么埃沃迪胺细胞外矩阵是细胞外矩阵.炎症炎症是一种炎症.椎间盘退化椎间盘退化这就是MAPKK的意思.线粒体中的线粒体.Nrf2 没有任何问题.

更多相关视频

A Proinflammatory, Degenerative Organ Culture Model to Simulate Early-Stage Intervertebral Disc Disease.

A Proinflammatory, Degenerative Organ Culture Model to Simulate Early-Stage Intervertebral Disc Disease.

Published on: February 14, 2021

Optical Sectioning and Visualization of the Intervertebral Disc from Embryonic Development to Degeneration

Optical Sectioning and Visualization of the Intervertebral Disc from Embryonic Development to Degeneration

Published on: July 8, 2021

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...